Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$1.63−0.06 (-3.55%)
Close on Nov 17, 2026Market cap $2.66MP/E –Yield –
Ernexa Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ernexa Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.84M. For fiscal 2025 it was -$7.02M. The highest annual figure on record is $2.83M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.02M | – |
| FY2024 | Dec 31, 2024 | -$15.84M | – |
| FY2023 | Dec 31, 2023 | -$20.41M | – |
| FY2022 | Dec 31, 2022 | -$20.98M | – |
| FY2021 | Dec 31, 2021 | -$23.49M | – |
| FY2020 | Dec 31, 2020 | -$8.10M | -395.2% |
| FY2019 | Dec 31, 2019 | $2.74M | +101.0% |
| FY2018 | Dec 31, 2018 | $1.37M | +148.6% |
| FY2017 | Dec 31, 2017 | $549.00K | +2287.0% |
| FY2016 | Dec 31, 2016 | $23.00K | – |
| FY2015 | Dec 31, 2015 | -$4.18M | – |
| FY2014 | Dec 31, 2014 | -$6.39M | -466.7% |
| FY2013 | Dec 31, 2013 | $1.74M | -19.2% |
| FY2012 | Dec 31, 2012 | $2.16M | +275.6% |
| FY2011 | Dec 31, 2011 | $574.00K | -79.7% |
| FY2010 | Dec 31, 2010 | $2.83M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.07M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.64M | -266.6% |
| Q3 FY2020 | Sep 30, 2020 | -$2.41M | -670.3% |
| Q2 FY2020 | Jun 30, 2020 | -$2.18M | -490.6% |
| Q1 FY2020 | Mar 31, 2020 | -$1.87M | -340.1% |
| Q4 FY2019 | Dec 31, 2019 | $983.00K | +17.4% |
| Q3 FY2019 | Sep 30, 2019 | $422.00K | +46.0% |
| Q2 FY2019 | Jun 30, 2019 | $559.00K | +55.7% |
| Q1 FY2019 | Mar 31, 2019 | $780.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $837.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $289.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $359.00K | -89.0% |
| Q1 FY2018 | Mar 31, 2018 | -$120.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$507.00K | -1094.1% |
| Q3 FY2017 | Sep 30, 2017 | -$1.75M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$466.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $51.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$41.00K | – |
See a number that looks wrong?